Skip to main content

IMPERIAL randomized controlled trial results

Eluvia DES demonstrated statistically significant difference in primary patency versus Zilver PTX and achieved the highest primary patency reported in any SFA DE Pivotal Trial at 1-Year.7,8,9,10

The IMPERIAL RCT demonstrated that Eluvia DES is clinically effective and safe in treating patients with symptomatic SFA disease both in the short-term during the height of restenosis risk, and long-term out to five years.

IMPERIAL RCT 1-year primary patency results

Chart with Primary Patency Results* 92.1% Eluvia DES 81.8% Zilver PTX

IMPERIAL RCT 2-year primary patency results¹²

Imperial RCT 2 year results, showing Eluvia with highest primary patency.

2-year clinically-driven TLR

Eluvia DES had statistically significant fewer CD-TLRs compared to Zilver PTX at 2-Years.16

Bar chart showing clinically driven TLR 37% reduction for Eluvia DES

IMPERIAL randomized controlled trial details

2-Year Primary EndpointsEluvia DES
Zilver PTX 
Primary Patency83.0%77.1%0.1008
Major Adverse Events14.2%20.1%0.1236
Mortality RatesEluvia DESZilver PTXp-value
1-Year All-Cause Mortality2.1%4.0%0.23
2-Year All-Cause Mortality7.1%
Baseline Characteristics

Eluvia DES

Zilver PTX 

Age (Years)68.5 ± 9.567.8 ± 9.4
Male Gender66.0%66.7%
Diabetes Mellitus41.7%43.6%
History of Smoking86.1%84.0%
Target Lesion Length (mm)86.5 ± 36.981.8 ± 37.3
Severely Calcified40.1%32.3%
Total Occlusions31.2%30.3%
Extending into Distal SFA66.3%65.4%

Ordering and reimbursement

Get downloads for ordering information and reimbursement coding guides for our drug-eluting technologies.

Stay up to date

Receive emails about the latest drug-eluting technology news, innovations and events in your area.

7. Gray W. 2-year Outcomes from the IMPERIAL Randomized Head to Head Study of Eluvia DES and Zilver PTX; LINC 2020, Leipzig Jan 28,2020.

8. Kaplan-Meier Primary Patency Estimate through 1-Year (including follow-up window) was statistically significant with a p-value of 0.0094.

9. Based on 1-Year Kaplan-Meier estimates reported for IMPERIAL, RANGER II SFA, IN.PACT SFA, ILLUMENATE, LEVANT II and Primary Randomization for Zilver PTX RCT.

10. Kaplan Meier Estimate; Primary patency as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) is ≤ 2.4 at the 1-Year follow-up visit, in the absence of clinically-driven TLR or bypass of the target lesion.

11. Log-rank p-value compares the entire K-M curves from time zero to full 1-Year follow-up window.

12. Intention to treat. Adapted from Iida, O VIVA 2019 Presentation. Kaplan-Meier estimate utilizing time-to-event of clinically-driven TLR up to 730 days and Duplex Ultrasound data at 2-Years. Primary patency defined as duplex ultrasound PSVR ≤2.4, in the absence of clinically-driven target lesion revascularization or bypass of the target lesion, as assessed by the DUS core lab.

13. In IMPERIAL RCT, Eluvia K-M Primary Patency was 83.0% vs. 77.1% for Zilver PTX at 2-Years, p=0.1008.

14. Vermassen, F. VIVA Late-Breaking Clinical Trials June 2020.

15. Iida, O. IMPERIAL Head to Head Randomized Study of Eluvia and Zilver PTX. Two-Year Outcomes & Japanese Patients. JET 2020.

16. Intention to treat. Iida O, VIVA 2019. RCT, randomized controlled trial; TLR, target lesion revascularization.

17. Gray, W. 2 year Outcomes from the IMPERIAL Randomized Head to Head Study of Eluvia DES and Zilver PTX. LINC 2020.